Oppenheimer & CO Inc Aerie Pharmaceuticals Inc Transaction History

Oppenheimer & CO Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 03, 2021	SELL	$15.16 - $18.97 $151,600 - $189,700	-10,000 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$13.12 - $20.9 $131,200 - $209,000	10,000 New	10,000 $178,000
Q4 2020 Feb 11, 2021	SELL	$9.12 - $14.49 $92,567 - $147,073	-10,150 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$10.46 - $14.46 $1,046 - $1,446	100 Added 1.0%	10,150 $119,000
Q2 2020 Aug 11, 2020	SELL	$12.0 - $16.13 $29,400 - $39,518	-2,450 Reduced 19.6%	10,050 $148,000
Q1 2020 May 08, 2020	SELL	$11.84 - $25.52 $39,072 - $84,216	-3,300 Reduced 20.89%	12,500 $168,000
Q4 2019 Feb 07, 2020	SELL	$17.72 - $25.1 $108,003 - $152,984	-6,095 Reduced 27.84%	15,800 $382,000
Q3 2019 Oct 31, 2019	SELL	$18.41 - $28.0 $135,479 - $206,052	-7,359 Reduced 25.16%	21,895 $421,000
Q2 2019 Aug 09, 2019	BUY	$28.97 - $48.21 $650,695 - $1.08 Million	22,461 Added 330.65%	29,254 $864,000
Q1 2019 Apr 24, 2019	BUY	$36.32 - $49.25 $246,721 - $334,555	6,793 New	6,793 $323,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.